Cargando…

Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics

OBJECTIVE: Aberrant activity of androgen receptor (AR) is the primary cause underlying development and progression of prostate cancer (PCa) and castration-resistant PCa (CRPC). Androgen signaling regulates gene transcription and lipid metabolism, facilitating tumor growth and therapy resistance in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Chianese, Ugo, Papulino, Chiara, Passaro, Eugenia, Evers, Tom MJ., Babaei, Mehrad, Toraldo, Antonella, De Marchi, Tommaso, Niméus, Emma, Carafa, Vincenzo, Nicoletti, Maria Maddalena, Del Gaudio, Nunzio, Iaccarino, Nunzia, Randazzo, Antonio, Rotili, Dante, Mai, Antonello, Cappabianca, Salvatore, Mashaghi, Alireza, Ciardiello, Fortunato, Altucci, Lucia, Benedetti, Rosaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403566/
https://www.ncbi.nlm.nih.gov/pubmed/35944897
http://dx.doi.org/10.1016/j.molmet.2022.101561
_version_ 1784773405864624128
author Chianese, Ugo
Papulino, Chiara
Passaro, Eugenia
Evers, Tom MJ.
Babaei, Mehrad
Toraldo, Antonella
De Marchi, Tommaso
Niméus, Emma
Carafa, Vincenzo
Nicoletti, Maria Maddalena
Del Gaudio, Nunzio
Iaccarino, Nunzia
Randazzo, Antonio
Rotili, Dante
Mai, Antonello
Cappabianca, Salvatore
Mashaghi, Alireza
Ciardiello, Fortunato
Altucci, Lucia
Benedetti, Rosaria
author_facet Chianese, Ugo
Papulino, Chiara
Passaro, Eugenia
Evers, Tom MJ.
Babaei, Mehrad
Toraldo, Antonella
De Marchi, Tommaso
Niméus, Emma
Carafa, Vincenzo
Nicoletti, Maria Maddalena
Del Gaudio, Nunzio
Iaccarino, Nunzia
Randazzo, Antonio
Rotili, Dante
Mai, Antonello
Cappabianca, Salvatore
Mashaghi, Alireza
Ciardiello, Fortunato
Altucci, Lucia
Benedetti, Rosaria
author_sort Chianese, Ugo
collection PubMed
description OBJECTIVE: Aberrant activity of androgen receptor (AR) is the primary cause underlying development and progression of prostate cancer (PCa) and castration-resistant PCa (CRPC). Androgen signaling regulates gene transcription and lipid metabolism, facilitating tumor growth and therapy resistance in early and advanced PCa. Although direct AR signaling inhibitors exist, AR expression and function can also be epigenetically regulated. Specifically, lysine (K)-specific demethylases (KDMs), which are often overexpressed in PCa and CRPC phenotypes, regulate the AR transcriptional program. METHODS: We investigated LSD1/UTX inhibition, two KDMs, in PCa and CRPC using a multi-omics approach. We first performed a mitochondrial stress test to evaluate respiratory capacity after treatment with MC3324, a dual KDM-inhibitor, and then carried out lipidomic, proteomic, and metabolic analyses. We also investigated mechanical cellular properties with acoustic force spectroscopy. RESULTS: MC3324 induced a global increase in H3K4me2 and H3K27me3 accompanied by significant growth arrest and apoptosis in androgen-responsive and -unresponsive PCa systems. LSD1/UTX inhibition downregulated AR at both transcriptional and non-transcriptional level, showing cancer selectivity, indicating its potential use in resistance to androgen deprivation therapy. Since MC3324 impaired metabolic activity, by modifying the protein and lipid content in PCa and CRPC cell lines. Epigenetic inhibition of LSD1/UTX disrupted mitochondrial ATP production and mediated lipid plasticity, which affected the phosphocholine class, an important structural element for the cell membrane in PCa and CRPC associated with changes in physical and mechanical properties of cancer cells. CONCLUSIONS: Our data suggest a network in which epigenetics, hormone signaling, metabolite availability, lipid content, and mechano-metabolic process are closely related. This network may be able to identify additional hotspots for pharmacological intervention and underscores the key role of KDM-mediated epigenetic modulation in PCa and CRPC.
format Online
Article
Text
id pubmed-9403566
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94035662022-08-26 Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics Chianese, Ugo Papulino, Chiara Passaro, Eugenia Evers, Tom MJ. Babaei, Mehrad Toraldo, Antonella De Marchi, Tommaso Niméus, Emma Carafa, Vincenzo Nicoletti, Maria Maddalena Del Gaudio, Nunzio Iaccarino, Nunzia Randazzo, Antonio Rotili, Dante Mai, Antonello Cappabianca, Salvatore Mashaghi, Alireza Ciardiello, Fortunato Altucci, Lucia Benedetti, Rosaria Mol Metab Original Article OBJECTIVE: Aberrant activity of androgen receptor (AR) is the primary cause underlying development and progression of prostate cancer (PCa) and castration-resistant PCa (CRPC). Androgen signaling regulates gene transcription and lipid metabolism, facilitating tumor growth and therapy resistance in early and advanced PCa. Although direct AR signaling inhibitors exist, AR expression and function can also be epigenetically regulated. Specifically, lysine (K)-specific demethylases (KDMs), which are often overexpressed in PCa and CRPC phenotypes, regulate the AR transcriptional program. METHODS: We investigated LSD1/UTX inhibition, two KDMs, in PCa and CRPC using a multi-omics approach. We first performed a mitochondrial stress test to evaluate respiratory capacity after treatment with MC3324, a dual KDM-inhibitor, and then carried out lipidomic, proteomic, and metabolic analyses. We also investigated mechanical cellular properties with acoustic force spectroscopy. RESULTS: MC3324 induced a global increase in H3K4me2 and H3K27me3 accompanied by significant growth arrest and apoptosis in androgen-responsive and -unresponsive PCa systems. LSD1/UTX inhibition downregulated AR at both transcriptional and non-transcriptional level, showing cancer selectivity, indicating its potential use in resistance to androgen deprivation therapy. Since MC3324 impaired metabolic activity, by modifying the protein and lipid content in PCa and CRPC cell lines. Epigenetic inhibition of LSD1/UTX disrupted mitochondrial ATP production and mediated lipid plasticity, which affected the phosphocholine class, an important structural element for the cell membrane in PCa and CRPC associated with changes in physical and mechanical properties of cancer cells. CONCLUSIONS: Our data suggest a network in which epigenetics, hormone signaling, metabolite availability, lipid content, and mechano-metabolic process are closely related. This network may be able to identify additional hotspots for pharmacological intervention and underscores the key role of KDM-mediated epigenetic modulation in PCa and CRPC. Elsevier 2022-08-06 /pmc/articles/PMC9403566/ /pubmed/35944897 http://dx.doi.org/10.1016/j.molmet.2022.101561 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Chianese, Ugo
Papulino, Chiara
Passaro, Eugenia
Evers, Tom MJ.
Babaei, Mehrad
Toraldo, Antonella
De Marchi, Tommaso
Niméus, Emma
Carafa, Vincenzo
Nicoletti, Maria Maddalena
Del Gaudio, Nunzio
Iaccarino, Nunzia
Randazzo, Antonio
Rotili, Dante
Mai, Antonello
Cappabianca, Salvatore
Mashaghi, Alireza
Ciardiello, Fortunato
Altucci, Lucia
Benedetti, Rosaria
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
title Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
title_full Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
title_fullStr Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
title_full_unstemmed Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
title_short Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
title_sort histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403566/
https://www.ncbi.nlm.nih.gov/pubmed/35944897
http://dx.doi.org/10.1016/j.molmet.2022.101561
work_keys_str_mv AT chianeseugo histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT papulinochiara histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT passaroeugenia histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT everstommj histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT babaeimehrad histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT toraldoantonella histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT demarchitommaso histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT nimeusemma histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT carafavincenzo histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT nicolettimariamaddalena histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT delgaudionunzio histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT iaccarinonunzia histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT randazzoantonio histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT rotilidante histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT maiantonello histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT cappabiancasalvatore histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT mashaghialireza histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT ciardiellofortunato histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT altuccilucia histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics
AT benedettirosaria histonelysinedemethylaseinhibitionreprogramsprostatecancermetabolismandmechanics